Merck and Samsung Bioepis Enter Biosimilars Development and Commercialization Agreement

  Merck and Samsung Bioepis Enter Biosimilars Development and
  Commercialization Agreement

Business Wire

WHITEHOUSE STATION, N.J. & SEOUL, South Korea -- February 20, 2013

Merck, (NYSE: MRK) known as MSD outside the United States and Canada, and
Samsung Bioepis Co., Ltd., entered into an agreement to develop and
commercialize multiple pre-specified and undisclosed biosimilar candidates.

“The combination of Merck’s global commercial presence with Samsung Bioepis’
biologic development and manufacturing capabilities positions the two
companies well to increase access to biosimilars to improve human health,”
said Rich Murray, Ph.D., senior vice president, biologics and vaccines
research, Merck Research Laboratories. “We look forward to this collaboration
and its potential to complement our expanding internal biologics portfolio.”

Under the agreement, Samsung Bioepis will be responsible for preclinical and
clinical development, process development and manufacturing, clinical trials
and registration. Merck will be responsible for commercialization. Samsung
Bioepis will receive an upfront payment from Merck, product supply income and
will be eligible for additional payments associated with pre-specified
clinical and regulatory milestones. Further financial terms were not

“Samsung Bioepis has been buildingthe capabilities needed to develop
high-quality biosimilars,” said Christopher Hansung Ko, Ph.D., CEO of Samsung
Bioepis. “With this development andcommercialization agreement, Samsung takes
a significant step toward becoming a major player in the biopharmaceutical

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside of the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit and
connect with us on Twitter, Facebook and YouTube.

About Samsung Bioepis

Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec,
aims to develop affordable and high-quality biopharmaceutical and biosimilar
products. For more information, please visit

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline products
that the products will receive the necessary regulatory approvals or that they
will prove to be commercially successful. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may differ
materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck’s
patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2011
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site

Photos/Multimedia Gallery Available:



Merck Media Relations:
Ronald Rogers, 908-423-6449
Merck Investor Relations:
Justin Holko, 908-423-5088
Samsung Bioepis:
HongSeok Ji, +82-32-455-6102
Press spacebar to pause and continue. Press esc to stop.